Additionally, ALM tumors tend to harbor fewer tumor-infiltrating lymphocytes, critical for the efficacy of immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 [64]. This evidence concerns the gene PDCD1 and acral lentiginous melanoma.